Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration
The DOI matches its Crossref record.
Abstract
Article AbstractObjective: The maintenance efficacy of antidepressants is usually assessed in postmarketing studies with a randomized withdrawal design. This report explores differences in relapse rates, trial characteristics, and success rates in maintenance efficacy studies submitted to the US Food and Drug Administration (FDA) over a 25-year period. Data Sources: Clinical data from all maintenance trials with antidepressants submitted to FDA between 1987 and 2012. Study Selection: Efficacy data were compiled from 15 maintenance clinical trials in adults diagnosed with major depressive disorder according to DSM-III or DSM-IV criteria. Data Extraction: Trial characteristics, relapse rates, and time to relapse in each study were examined. Results: Relapse rates were significantly lower (P < .05) in the drug arm than in the placebo arm in every study, with a mean relapse rate difference of 18% and an average percent reduction in relapse rate of 52% compared to placebo. Only 6% of the relapse events occurred in the first 2 weeks of the double-blind phase. The separation between treatment arms continued to increase throughout the double-blind phase only in the trial with longest response stabilization period. Conclusions: Antidepressant maintenance trials have a high rate of success, indicating a benefit of continuing drug treatment after initial response to an antidepressant. This benefit appears to result mainly from a decreased rate of recurrent depression rather than from an effect of drug withdrawal in the placebo groups. J Clin Psychiatry 2014;75(3):205-214 © Copyright 2014 Physicians Postgraduate Press, Inc. Submitted: August 7, 2013; accepted November 27, 2013 (doi:10.4088/JCP.13r08722). Corresponding author: Silvana Borges, MD, Division of Psychiatry Products, HFD-130, Food and Drug Administration, 10903 New Hampshire Ave, Bldg 22, Rm 4159, Silver Spring, MD 20993-0002 (silvana.borges@fda.hhs.gov).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a result, the relapse rate in the antidepressant arm was about 20% lower than that in the placebo arm and the difference in relapse rate between them after 6 months was maintained.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [11]
In the citing paper
“Borges et al. focused on RCTs of enrichment design only [11], using 15 unpublished drug application studies submitted to the FDA.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [11]
In the citing paper
“However, we believe that this risk is not significant because our subanalysis showed that dropout rates did not change in abrupt discontinuation trials and that withdrawal symptoms did not affect relapse in the short term results as seen in Borges et al. [11]”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [11]
In the citing paper
“In fact, a meta-analysis by Sim et al. showed that 6 of the 15 studies submitted to the FDA by Borges et al. had the same number of subjects as the other published studies included in their meta-analysis.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [11]
In the citing paper
“Moreover, they used the data from Borges et al.’s study which risks the possibility of duplicate analysis.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [11]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Still being checked.
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Management of Depression in Older Adults: A Review
Kok, R. M., & Reynolds, C. F. (2017) · JAMA · doi:10.1001/jama.2017.5706 · Cited by 890
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
Metadata
- Authors
- Borges, S., Chen, Y.-F., Laughren, T. P., Temple, R., Patel, H. D., David, P. A., Mathis, M., Unger, E., Yang, P., & Khin, N. A.
- Affiliations
- United States Food and Drug Administration (US)
- Corresponding author
- Borges, Silvana
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-03-15
- Volume
- 75
- Issue
- 03
- Pages
- 205-214
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1968103182
- Cited by
- 109
- References
- 0
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 5 · 2023: 8 · 2022: 9 · 2021: 7 · 2020: 11 · 2019: 19 · 2018: 10 · 2017: 12 · 2016: 11 · 2015: 8 · 2014: 3
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- major depressive disorder, antidepressant maintenance, relapse rate, recurrent depression, time to relapse, drug withdrawal, post-marketing studies
- MeSH terms
- Adult, Major Depressive Disorder, Depressive Disorder, Major, Female, Humans, Male, Middle Aged, Time Factors, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Treatment Outcome, Withholding Treatment, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration. https://app.cochat.ai/papers/10.4088/jcp.13r08722
- The paper
- Borges, S., Chen, Y.-F., Laughren, T. P., Temple, R., Patel, H. D., David, P. A., Mathis, M., Unger, E., Yang, P., & Khin, N. A. (2014). Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.13r08722
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.